188 related articles for article (PubMed ID: 8664034)
1. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan.
Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N
Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034
[TBL] [Abstract][Full Text] [Related]
2. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.
Toi M; Hattori T; Akagi M; Inokuchi K; Orita K; Sugimachi K; Dohi K; Nomura Y; Monden Y; Hamada Y
Cancer; 1992 Nov; 70(10):2475-83. PubMed ID: 1423177
[TBL] [Abstract][Full Text] [Related]
3. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Nishinihon Cooperative Study Group of Adjuvant Therapy for Breast Cancer.
Sugimachi K; Maehara Y; Akazawa K; Nomura Y; Eida K; Ogawa M; Konaga E; Tanaka N; Toge T; Dohi K; Noda S; Maeda M; Monden Y
Breast Cancer Res Treat; 1999 Jul; 56(2):113-24. PubMed ID: 10573104
[TBL] [Abstract][Full Text] [Related]
4. [A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan].
Yoshida M; Saji S; Takagi H; Takeuchi S; Tsuda H; Nimura Y; Mizumoto R; Miyazaki I; Kobayashi S; Noguchi M
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2325-33. PubMed ID: 8259846
[TBL] [Abstract][Full Text] [Related]
5. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
Nomura Y; Shirouzu M; Takayama T
Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Cancer; 1988 Jun; 61(11):2168-75. PubMed ID: 3130175
[TBL] [Abstract][Full Text] [Related]
7. A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan.
Abe R; Tsuchiya A; Koie H; Ono K; Abo S; Saito K; Tsukamoto M; Sato T; Mori S; Kikuchi K
Am J Clin Oncol; 1994 Apr; 17(2):103-8. PubMed ID: 8141101
[TBL] [Abstract][Full Text] [Related]
8. Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
Uchino J; Samejima N; Tanabe T; Hayasaka H; Mito M; Hata Y; Asaishi K
Br J Cancer; 1994 Apr; 69(4):767-71. PubMed ID: 8142265
[TBL] [Abstract][Full Text] [Related]
9. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
10. UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group.
Hata Y; Uchino J; Asaishi K; Kubo Y; Mito M; Tanabe T; Ogita M; Hirata K
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):91-5. PubMed ID: 10442372
[TBL] [Abstract][Full Text] [Related]
11. Meta-Analysis of the Second Collaborative Study of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) in Patients with Stage II, Estrogen-Receptor-Positive Breast Cancer.
Yoshida M; Abe O; Uchino J; Kikuchi K; Abe R; Enomoto K; Tominaga T; Fukami A; Sugimachi K; Nomura Y; Hattori T; Ogawa N
Breast Cancer; 1997 Jul; 4(2):93-101. PubMed ID: 11091583
[TBL] [Abstract][Full Text] [Related]
12. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.
Tormey DC; Gray R; Abeloff MD; Roseman DL; Gilchrist KW; Barylak EJ; Stott P; Falkson G
J Clin Oncol; 1992 Dec; 10(12):1848-56. PubMed ID: 1453199
[TBL] [Abstract][Full Text] [Related]
14. Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.
Park Y; Okamura K; Mitsuyama S; Saito T; Koh J; Kyono S; Higaki K; Ogita M; Asaga T; Inaji H; Komichi H; Kohno N; Yamazaki K; Tanaka F; Ito T; Nishikawa H; Osaki A; Koyama H; Suzuki T
Br J Cancer; 2009 Aug; 101(4):598-604. PubMed ID: 19638976
[TBL] [Abstract][Full Text] [Related]
15. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
[TBL] [Abstract][Full Text] [Related]
16. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
Nomura Y; Tsutsui S; Murakami S; Takenaka Y
Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer. Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer.
Sakai K; Kosaki G; Seno T; Taguchi T; Terasawa T; Nakao K; Koyama H; Oshima A
Cancer Chemother Pharmacol; 1996; 37(6):587-92. PubMed ID: 8612314
[TBL] [Abstract][Full Text] [Related]
18. The Role of Chemoendocrine Agents in Postoperative Adjuvant Therapy for Breast Cancer: Meta-analysis of the First Collaborative Studies of Postoperative Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC).
Abe O
Breast Cancer; 1994 Jul; P(P):P-P9. PubMed ID: 11091512
[TBL] [Abstract][Full Text] [Related]
19. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
20. Ten-year results of a randomized trial on adjuvant chemo-endocrine therapy with tamoxifen for stage II breast cancer.
Hata Y; Takahashi H; Todo S; Okazaki M; Asaishi K; Hirata K; Okushiba S; Kato H; Uchino J
Breast Cancer; 2003; 10(2):134-9. PubMed ID: 12736566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
